Cyclic Peptides and Macrocyclization, Explained

Peptide science

Cyclic peptides solve the single biggest weakness of peptide chemistry: linear peptides fall apart. Close the chain into a ring and you remove the free ends that exopeptidases attack, lock the molecule into a shape that binds harder, and — occasionally — make something that survives the gut. Nature figured this out long before medicinal chemists did, which is why so many antibiotics and toxins are rings. This guide covers how peptides are cyclized, what cyclization actually buys, and what it does not.

The five main ways to close a ring

Cyclization is a family of chemistries, not one reaction, and the differences matter both in the lab and on the mass spectrometer.

• Head-to-tail (backbone) cyclization joins the N-terminal amine to the C-terminal carboxyl, forming a macrolactam. Cyclosporine is the classic example.
• Side-chain-to-side-chain lactam joins an Asp or Glu carboxyl to a Lys amine. Bremelanotide uses this.
• Disulfide bridges oxidise two cysteine thiols together. Oxytocin, vasopressin, octreotide and linaclotide all rely on this.
• Thioether and lanthionine bridges appear in ribosomally synthesised bacteriocins. Nisin carries five, formed by dehydration followed by Michael addition.
• Hydrocarbon staples use ring-closing metathesis between two alkene-bearing unnatural residues to lock a helix. The all-hydrocarbon crosslink was first published in 2000.

There are also bicyclic peptides, head-to-side-chain lariats such as bacitracin, and macrolactones (esters rather than amides) like daptomycin.

What cyclization actually buys you

Protease resistance. A head-to-tail ring has no free N- or C-terminus, so aminopeptidases and carboxypeptidases have nothing to grip. The constrained backbone also makes it a poorer substrate for endopeptidases, which need to thread a peptide into an extended conformation.

Higher affinity through pre-organization. A linear peptide pays a large entropic penalty when it freezes into its bound conformation. A cyclic peptide has already paid part of that bill, so binding costs less free energy. This is why cyclization frequently improves both potency and selectivity rather than just stability.

Occasionally, membrane permeability. This is the least reliable benefit but the most interesting one, and it deserves its own section.

The chameleon: why cyclosporine is oral and almost nothing else is

Cyclosporin A is an 11-residue head-to-tail macrolactam with seven N-methylated amide nitrogens and a molecular weight around 1,203. By every classical rule it should not be orally absorbed.

It works because it changes shape with its environment. In water it adopts an open conformation with polar amide NH groups facing outward and hydrogen-bonding to solvent. In a low-polarity environment such as a lipid membrane, those same NH groups fold inward and hydrogen-bond to each other, burying the polarity and presenting a greasy exterior. This behaviour, now called molecular chameleonicity, is the central concept in what medicinal chemists call “beyond rule of 5” space. The N-methyl groups are part of the trick: they remove hydrogen-bond donors outright and give the backbone the flexibility to switch.

The honest caveat is that even cyclosporine is not a clean success. Its label describes absorption as erratic, and the widely quoted 30% oral bioavailability figure on the original formulation rests on results in two patients. Later formulations changed the picture again.

The natural cyclic peptides worth knowing

• Oxytocin and vasopressin are cyclic. Both are nonapeptides with a Cys1-Cys6 disulfide loop and a three-residue tail; the vasopressin label literally names it “Cyclo (1-6).” People often forget these are rings.
• Somatostatin-14 is a cyclic tetradecapeptide closed by a Cys3-Cys14 disulfide, with a half-life of one to three minutes.
• Polymyxin B and colistin are nonribosomal cyclic lipopeptides: a seven-residue ring, a linear tripeptide arm and a fatty acyl tail, with five diaminobutyric acid residues giving the polycationic charge. They differ from each other by a single ring residue.
• Daptomycin is a 13-residue macrolactone with a decanoyl tail.
• Alpha-amanitin, from the death cap mushroom, is a bicyclic octapeptide with a tryptathionine crossbridge that inhibits RNA polymerase II.
• Vancomycin is often lumped in with cyclic peptides, but its rings come from aryl side-chain crosslinks, not backbone amide closure. Its own label calls it a tricyclic glycopeptide. Worth being precise about.

How cyclization is actually done

The core difficulty is that macrocyclization is entropically unfavourable and always competes with intermolecular oligomerization. Two tricks address this.

Pseudo-dilution on resin. Forming the ring while the peptide is still attached to solid support keeps chains physically separated, suppressing dimerisation. Side-chain anchoring — tethering the peptide to the resin through a Glu, Asp, Lys, His or Ser side chain — leaves both termini free for head-to-tail closure.

High dilution in solution. Working concentrations are typically low millimolar, roughly 1 to 5 mM, often with slow addition of the substrate. Note that this is not micromolar; published macrocyclizations at 5 mM have reported only around 5% dimer.

Other routes include native chemical ligation (a thioester plus an N-terminal cysteine, undergoing an S-to-N acyl shift), copper-catalysed azide-alkyne cycloaddition, and thiol-ene chemistry. A 1,5-triazole spans about 4.1 to 4.2 Å between alpha carbons versus 3.9 to 4.0 Å for a disulfide, which is why triazoles work as disulfide surrogates.

Finding cyclic peptides: display technologies

Rational design only goes so far, so the field turned to selection. The RaPID system combines flexizyme-based genetic code reprogramming with mRNA display and can screen libraries of more than 10¹² unique macrocycles. SICLOPPS uses split inteins to make cyclic peptides inside living cells, with libraries around 10⁸ members, and can close rings as short as four residues. Phage display of bicyclic peptides underpins Bicycle Therapeutics, whose Nectin-4-targeted conjugate zelenectide pevedotin reported a 45% objective response rate at 5 mg/m² in 38 patients and is now in a phase 2/3 trial.

The most consequential product of this approach so far is enlicitide, an oral macrocyclic PCSK9 inhibitor originally discovered by mRNA display and then optimised by structure-based design. In phase 3 it lowered LDL cholesterol by 55.8% versus placebo at week 24, by 59.4% in heterozygous familial hypercholesterolaemia, and beat ezetimibe, bempedoic acid and their combination in a head-to-head study. An oral drug hitting a target that previously required injected antibodies is the strongest argument yet for the whole macrocyclic peptide field.

The limits

Cyclization does not guarantee oral bioavailability. Most approved cyclic peptides are still injectables, and two of the oral ones — linaclotide and plecanatide — work precisely because they are not absorbed, acting on guanylate cyclase C in the gut lining.

It also does not guarantee safety. Polymyxin nephrotoxicity is common: pooled prevalence estimates run around 27% for colistin and 30% for polymyxin B, and a meta-analysis using RIFLE criteria put the pooled figure at 45%. Vancomycin has a well-known renal profile of its own, and co-administration raises the risk.

One more caution on comparisons. Octreotide’s half-life of 1.7 to 1.9 hours against somatostatin’s 1 to 3 minutes is frequently cited as proof that cyclization extends half-life. It is not a fair comparison — somatostatin is itself cyclic. Octreotide’s advantage comes from truncation, D-amino acids, a smaller six-residue ring and a modified C-terminus. For the general principles, see peptide half-life explained.

Analytical and handling notes

• Mass changes are diagnostic, but not universal. Amide-bond closure loses one water molecule, about 18.0 Da. A disulfide loses only two hydrogens, about 2.0 Da. Ring-closing metathesis expels ethylene, about 28.1 Da. Do not apply the “18 Da lighter” rule to a disulfide-cyclized peptide.
• Disulfide scrambling is a real problem. At neutral-to-alkaline pH the thiolate anion drives thiol-disulfide exchange. A published kinetic study across pH 6.0 to 10.0 and 4 to 50 °C found that omitting oxidation suppressants such as EDTA and nitrogen sparging increased scrambled-disulfide formation.
• Reducing agents matter. Any disulfide-cyclized peptide is inherently unstable in a reducing environment and towards free thiols.
• For the analytical side, see peptide analysis methods, and use the reconstitution calculator or concentration converter for the arithmetic.

Frequently asked questions

Are cyclic peptides always more stable than linear ones?

Generally yes against exopeptidases, because the free termini are gone, and often against endopeptidases too because the constrained backbone resists the extended conformation those enzymes require. But the size of the improvement varies enormously by sequence and closure type, and disulfide-cyclized peptides remain vulnerable to reducing conditions.

Does making a peptide cyclic make it orally active?

Almost never on its own. Cyclosporine is the famous exception and it works through a specific conformational mechanism, helped by extensive N-methylation. Most approved cyclic peptides are still injected.

Why is a cyclic peptide 18 Da lighter than its linear version?

Only if it was closed with an amide bond, which releases one water molecule. Disulfide closure loses two hydrogen atoms (about 2 Da) and ring-closing metathesis expels ethylene (about 28 Da). Check which chemistry was used before interpreting a mass spectrum.

What are stapled peptides?

Peptides with a synthetic crosslink — usually an all-hydrocarbon bridge made by ring-closing metathesis between two alkene-bearing unnatural amino acids — installed to lock an alpha helix in place. The goal is helix stabilisation, protease resistance and, in some cases, cell entry.

Informational only — not medical advice · 21+. VialHelp does not sell peptides and does not recommend any product, brand or protocol. Drug information is summarised from public labels and published literature for educational context. Consult a qualified healthcare professional for personal medical questions.